Key result
Low-dose aspirin was associated with an increased risk of major gastrointestinal bleeding compared to placebo (RR 2.07; 95% CI 1.61-2.66), corresponding to an absolute annual rate increase of 0.12%.
Why the study?
Does low-dose aspirin increase the risk of gastrointestinal bleeding compared to placebo in patients requiring vascular protection?
Population
Patients taking low-dose aspirin for vascular protection
Comparison
Low-dose aspirin vs Placebo
Design
Review
Authors
Loading...
Demands individualized risk-benefit weighing for vascular protection; leaves optimal gastroprotection strategies open.
Does low-dose aspirin increase the risk of gastrointestinal bleeding compared to placebo in patients requiring vascular protection?
Effect estimate: RR 2.07 (95% CI 1.61-2.66)
Low-dose aspirin significantly increases the risk of major gastrointestinal bleeding, a risk that must be carefully weighed against its cardiovascular benefits for individual patients.
Loren Laine (2006) conducted a review in Gastrointestinal bleeding and ulcers. Low-dose aspirin vs. Placebo was evaluated on Major gastrointestinal bleeding (RR 2.07, 95% CI 1.61-2.66). Low-dose aspirin was associated with an increased risk of major gastrointestinal bleeding compared to placebo (RR 2.07; 95% CI 1.61-2.66), corresponding to an absolute annual rate increase of 0.12%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: